NEW YORK and LONDON, September 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following …

[Read more...] about Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc

NEW YORK and LONDON, August 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered …

[Read more...] about Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement

NEW YORK and LONDON, July 13, 2015 Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a …

[Read more...] about Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition